Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment
Nanomaterials,
Journal Year:
2025,
Volume and Issue:
15(2), P. 122 - 122
Published: Jan. 16, 2025
Nano-oncologic
vaccines
represent
a
groundbreaking
approach
in
the
field
of
cancer
immunotherapy,
leveraging
unique
advantages
nanotechnology
to
enhance
effectiveness
and
specificity
treatments.
These
utilize
nanoscale
carriers
deliver
tumor-associated
antigens
immunostimulatory
adjuvants,
facilitating
targeted
immune
activation
promoting
robust
antitumor
responses.
By
improving
antigen
presentation
localizing
within
tumor
microenvironment,
nano-oncologic
can
significantly
increase
efficacy
particularly
when
combined
with
other
treatment
modalities.
This
review
highlights
mechanisms
through
which
operate,
their
potential
overcome
existing
limitations
treatment,
ongoing
advancements
design.
Additionally,
it
discusses
delivery
approach,
such
as
EPR
effects,
pH
response,
ultrasonic
magnetic
response.
The
combination
therapy
effects
photothermal
therapy,
radiotherapy,
or
checkpoint
inhibitors
are
also
discussed.
Overall,
hold
great
promise
for
changing
landscape
advancing
personalized
medicine,
paving
way
more
effective
therapeutic
strategies
tailored
individual
patient
needs.
Language: Английский
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 216 - 216
Published: Feb. 7, 2025
Cancer
is
one
of
the
leading
causes
morbidity
and
mortality
globally,
responsible
for
approximately
10
million
deaths
in
2022
an
estimated
21
new
cases
2024.
Traditional
cancer
treatments
such
as
surgery,
radiation
therapy,
chemotherapy
often
present
limitations
efficacy
side
effects.
However,
immunotherapeutic
vaccines
have
emerged
a
promising
approach,
leveraging
body’s
immune
system
to
target
eliminate
cells.
This
review
examines
evolving
landscape
vaccines,
differentiating
between
preventive
therapeutic
strategies
highlighting
significance
tumor-specific
antigens,
including
tumor-associated
antigens
(TAAs)
neoantigens.
Recent
advancements
vaccine
technology,
particularly
through
nanotechnology,
resulted
development
nanovaccines,
which
enhance
antigen
stability,
optimize
delivery
cells,
promote
robust
responses.
Notably,
clinical
data
indicate
that
patients
receiving
checkpoint
inhibitors
can
achieve
overall
survival
rates
34.8
months
compared
just
15.7
traditional
therapies.
Despite
these
advancements,
challenges
remain,
immunosuppressive
tumor
microenvironment
heterogeneity.
Emerging
evidence
suggests
combining
nanovaccines
with
immunomodulators
may
by
overcoming
obstacles.
Continued
research
interdisciplinary
collaboration
will
be
essential
fully
exploit
promise
ultimately
more
effective
accessible
patients.
The
future
immunotherapy
appears
increasingly
hopeful
innovative
pave
way
enhanced
patient
outcomes
improved
quality
life
oncology.
Language: Английский
Advancements in the use of cancer nanovaccines: Comprehensive insights with focus on lung and colon cancer
Nanotechnology Reviews,
Journal Year:
2025,
Volume and Issue:
14(1)
Published: Jan. 1, 2025
Abstract
Cancer
remains
a
prima
facie
cause
of
morbidity
and
mortality
globally,
necessitating
efficient
medicaments.
The
inter-mechanisms
between
immune
system
cascade
the
ability
cancer
cells
to
evade
immunological
responses
pose
significant
challenge
in
developing
effective
treatments
despite
advanced
immunotherapy
treatments.
Intervention
nanotechnology
vaccine
is
area
interest
now
therefore,
we
have
summarized
recent
developments
nanovaccine.
article
provides
comprehensive
review
available
treatment
for
also
nanovaccine
usages
especially
non-small
cell
lung
colon
cancer,
emphasizing
on
their
development,
mechanisms
action,
diverse
range
health
applications.
highlights
different
types
nanocarriers,
such
as
protein-based
carriers,
liposomes,
polymers,
exosomes,
which
in-turn
act
deliver
tumor
antigens,
adjuvants,
or
immunomodulatory
agents
directly
targeted
sites
effectiveness
improving
immunotherapy.
promising
innovations
technology,
viz.
,
immunotherapeutic
nanovaccines,
stimulator
interferon
genes
agonist-based
vaccines,
nanogel
supporting
photo
thermal
therapy
been
addressed
detail.
summarizes
importance
biocompatibility
specificity
criterion
minimizing
adverse
effects
by
including
global
impact
nanovaccines
reducing
recurrence.
Language: Английский